Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Terminated 1Active not recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Plasma cell 1

Conditions

Precursor Cell Lymphoblastic Leukemia-Lymphoma 2Multiple Myeloma 2Leukemia, Myeloid, Acute 2Sarcoma, Myeloid 1Neoplasms, Plasma Cell 1Myelodysplastic Syndromes 1Lymphoma, Non-Hodgkin 1Leukemia, Myelomonocytic, Juvenile 1Leukemia, Myelogenous, Chronic, BCR-ABL Positive 1High Risk Hematologic Malignancy 1Congenital Abnormalities 1

Interventions

Dexamethasone 13Lenalidomide 11daratumumab 5carfilzomib 5Bortezomib 5Calcium Dobesilate 4Whole-Body Irradiation 3Tacrolimus 3Mycophenolic Acid 3Melphalan 3Cyclophosphamide 3ixazomib 2isatuximab 2fludarabine phosphate 2fludarabine 2belantamab mafodotin 2Etoposide 2venetoclax 1thymoglobulin 1selinexor 1pomalidomide 1poly ICLC 1citarinostat 1Transplantation 1Thalidomide 1Sirolimus 1Rituximab 1Positron Emission Tomography Computed Tomography 1Pharmaceutical Preparations 1Peripheral Blood Stem Cell Transplantation 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Active not recruiting × Neoplasms, Plasma Cell × Transplantation × Clear all
NCT01208662 2026-01-22

DFCI 10-106

Dana-Farber Cancer Institute

Phase 3 Active not recruiting
729 enrolled 29 charts
Plasma cell

Multiple Myeloma, Neoplasms, Plasma Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡